美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

2倍做多NVO ETF-Defiance

17.59

+2.8919.66%

盤後：19.191.60+9.10%19:59 EST

成交量：101.75萬

成交額：1,713.04萬

市值：5,097.76萬

市盈率：- -

高：17.61

開：16.70

低：16.36

收：14.70

52周最高：105.60

52周最低：14.59

股本：289.81萬

流通股本：279.81萬

量比：0.62

換手率：36.36%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

GSK大裁員，周虹離開默克加入諾和諾德，華潤三九、正大清江、奇正藏藥三款產品暫停採購

同為減肥藥巨頭，諾和諾德市值不及禮來的1/5……

諾和諾德聯合減重療法臨牀3期結果積極；輝瑞超長效GLP-1受體激動劑將啓動3期試驗…… | TIDES周報

行業研究 | 2026 年 FDA 多肽新藥展望：6 款潛力產品引領行業破局

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/NVOX"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVOX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOX\",,,,,undefined,":{"symbol":"NVOX","market":"US","secType":"STK","nameCN":"2倍做多NVO ETF-Defiance","latestPrice":17.59,"timestamp":1770411600000,"preClose":14.7,"halted":0,"volume":1017450,"hourTrading":{"tag":"盘后","latestPrice":19.19,"preClose":17.59,"latestTime":"19:59 EST","volume":60982,"amount":1153960.0371,"timestamp":1770425948484,"change":1.6,"changeRate":0.090961,"amplitude":0.127914},"delay":0,"changeRate":0.19659863945578235,"floatShares":2798101,"shares":2898100,"eps":0,"marketStatus":"休市中","change":2.89,"latestTime":"02-06 16:00:00 EST","open":16.7,"high":17.61,"low":16.36,"amount":17130440.38545,"amplitude":0.085034,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":2,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":14.7,"sharesOutstanding":2818101,"nav":14.67,"aum":41341541.67,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":16.73,"preClose":14.7,"latestTime":"09:29 EST","volume":114049,"amount":1878015.002162,"timestamp":1770388174508,"change":2.03,"changeRate":0.138095,"amplitude":0.034694},"postHourTrading":{"tag":"盘后","latestPrice":19.19,"preClose":17.59,"latestTime":"19:59 EST","volume":60982,"amount":1153960.0371,"timestamp":1770425948484,"change":1.6,"changeRate":0.090961,"amplitude":0.127914},"volumeRatio":0.6174747072051386,"impliedVol":0.8418,"impliedVolPercentile":0.524},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOX\",,,,,undefined,":{"symbol":"NVOX","floatShares":2798101,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.6174747072051386,"shares":2898100,"dividePrice":0,"high":17.61,"amplitude":0.085034,"preClose":14.7,"low":16.36,"week52Low":14.5902,"pbRate":"--","week52High":105.6,"institutionHeld":0,"latestPrice":17.59,"eps":0,"divideRate":0,"volume":1017450,"delay":0,"ttmEps":0,"open":16.7,"prevYearClose":21.89,"prevWeekClose":28.89,"prevMonthClose":28.89,"prevQuarterClose":21.89,"fiveDayClose":28.89,"twentyDayClose":27.54,"sixtyDayClose":18.72},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVOX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-12-09","symbol":"NVOX","defaultRemindTime":1765290600000,"type":"split","dateTimestamp":1765256400000,"forFactor":8,"toFactor":1,"ratio":8}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVOX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVOX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVOX\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609575408","title":"GSK大裁員，周虹離開默克加入諾和諾德，華潤三九、正大清江、奇正藏藥三款產品暫停採購","url":"https://stock-news.laohu8.com/highlight/detail?id=2609575408","media":"药经说","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609575408?lang=zh_tw&edition=fundamental","pubTime":"2026-02-08 17:30","pubTimestamp":1770543018,"startTime":"0","endTime":"0","summary":"华润三九、正大清江、奇正藏药三款产品暂停采购2 月 3 日，上海药事所发布《关于暂停部分药品采购资格的通知》，根据国家局相关文件精神，暂停部分药品的采购资格。从附表来看，暂停采购药品包括华润三九医药股份有限公司的小柴胡颗粒、江苏正大清江制药有限公司的盐酸氨基葡萄糖片、西藏奇正藏药股份有限公司的消痛贴膏。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020817435495404dbc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020817435495404dbc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765489.SGD","LU1037948541.HKD","LU1430594728.SGD","IE00BSNM7G36.USD","BK4532","LU2324357040.USD","SG9999014542.SGD","IE0002141913.USD","SG9999001176.SGD","LU1917777945.USD","IE00BJT1NW94.SGD","LU1934455194.USD","IE00B1BXHZ80.USD","LU0208291251.USD","NVO","IE00B4R5TH58.HKD","IE00BLSP4239.USD","LU1291159041.SGD","BK4007","BK4585","LU0130517989.USD","IE00BN8TJ469.HKD","LU0980610538.SGD","LU0965509101.SGD","LU1571399168.USD","LU0432979614.USD","LU1585245621.USD","LU1116320901.HKD","LU1699723380.USD","LU0965509283.SGD","IE000M9KFDE8.USD","LU0477156953.USD","SG9999014559.SGD","SG9999014567.USD","BK4599","LU1116320737.USD","SG9999013999.USD","SG9999014575.USD","LU1069347547.HKD","IE00BZ1G4Q59.USD","LU0648001328.SGD","BK4534","LU1974910355.USD","LU0265550946.USD","IE0009355771.USD","LU1093756168.USD","SGXZ57979304.SGD","LU0154236417.USD","LU2468319806.SGD","LU1934455277.USD","LU0238689110.USD","LU0861579265.USD","LU2361044865.SGD","LU2023250504.SGD","BK4588","LU0106261372.USD","LU0058720904.USD","SG9999002232.USD","GSK","LU2461242641.AUD","LU0203345920.USD","LU1066053197.SGD","LU1989772923.USD","NVOH","SG9999002224.SGD","LU2112291526.USD","SG9999015341.SGD","IE00BLSP4452.SGD","LU2360032135.SGD","LU2361044949.HKD","IE00BKVL7J92.USD","LU0266013472.USD","LU0320765646.SGD","LU2089984988.USD","LU2023250843.SGD","BK4550","LU2106854487.HKD","LU2361045086.USD","LU1057294990.SGD","IE00BFTCPJ56.SGD","LU2125154778.USD","LU0098860793.USD","LU0265550359.USD","LU1066051225.USD","LU1934455863.HKD","LU1066051498.USD","LU0985320562.USD","LU0006306889.USD","LU1989771016.USD","LU1037948897.HKD","NVOX","LU1023059063.AUD","LU1093756325.SGD","IE00BBT3K403.USD","BK4559","LU2125154935.USD","GSK.UK","LU0070302665.USD","LU1829250122.USD","IE00BJJMRZ35.SGD","LU0965509010.AUD","IE00B2B36J28.USD","LU1941712348.USD","LU0289739699.SGD","LU1989772840.SGD","LU1162221912.USD","000999","LU0234572021.USD","SG9999001176.USD","LU0130102774.USD","LU1941712264.USD","LU1983299246.USD","LU0965508806.USD","SG9999015358.SGD","LU0211331839.USD","SG9999001440.SGD","LU1061106388.HKD","LU1066051811.HKD","LU1035773651.USD","LU1201861249.SGD","LU1929549753.HKD","BK4516","LU0203347892.USD","BK4533","LU0122379950.USD"],"gpt_icon":0},{"id":"2609515522","title":"同為減肥藥巨頭，諾和諾德市值不及禮來的1/5……","url":"https://stock-news.laohu8.com/highlight/detail?id=2609515522","media":"医药财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609515522?lang=zh_tw&edition=fundamental","pubTime":"2026-02-08 08:58","pubTimestamp":1770512301,"startTime":"0","endTime":"0","summary":"凭借减肥药风光无限的丹麦巨头诺和诺德，其市值竟然仅是美国竞争对手礼来的约五分之一。礼来预测今年营收将增长约25%，而诺和诺德却警告称销售额可能下降5%至13%。诺和诺德虽然率先推出了口服GLP-1药物Wegovy，但礼来预计将在2026年第二季度获得其口服药物orforglipron的批准。更令人担忧的是，诺和诺德在美国市场的份额正在被礼来侵蚀。这一协议预计将影响两家公司的收入，但对诺和诺德的冲击更为明显。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260208092058a4899dde&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260208092058a4899dde&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0225283273.USD","LU0316494557.USD","LU0672654240.SGD","LLYZ","LU2063271972.USD","BK4533","IE00BZ1G4Q59.USD","LU1023059063.AUD","LU2028103732.USD","IE00BFTCPJ56.SGD","LU0471298777.SGD","LU2471134952.CNY","LU0158827948.USD","LU0109391861.USD","LU2111349929.HKD","NVO","LU2237443465.HKD","LU2468319806.SGD","LU2756315318.SGD","LU1868836757.USD","LU1291159041.SGD","LU0820561909.HKD","LU1989771016.USD","LU0820562030.AUD","LU0353189680.USD","LU2168564065.EUR","LU2361044865.SGD","LU2471134879.HKD","LU2552382215.SGD","LU0471298694.HKD","LU0354030438.USD","LU0198837287.USD","LU0964807845.USD","SGXZ57979304.SGD","LU0096364046.USD","LU0354030511.USD","LU0097036916.USD","LU2264538146.SGD","BK4581","LU2168564495.EUR","LU2237443895.HKD","SGXZ51526630.SGD","LU1868836914.USD","LU1804176565.USD","LU2112291526.USD","SG9999014914.USD","LU0323591593.USD","LU2750360641.GBP","LU0256863902.USD","SGXZ99366536.SGD","LU2236285917.USD","IE00BK4W5M84.HKD","LU0689472784.USD","LU0058720904.USD","LU2324357040.USD","IE00BKDWB100.SGD","LU1988902786.USD","LU1035775433.USD","SG9999001176.SGD","LU0823434740.USD","IE00B2B36J28.USD","LU1629891620.HKD","LU2168563687.JPY","LU2237443549.SGD","IE0009355771.USD","BK4588","LU1323610961.USD","BK4585","IE00B1BXHZ80.USD","IE00BWXC8680.SGD","LU2417539215.USD","LU2491050071.SGD","IE0004445239.USD","NVOX","SG9999014898.SGD","LU1061106388.HKD","LU2089284900.SGD","IE00B4R5TH58.HKD","LU0122379950.USD","LU0823416689.USD","LU1720051017.SGD","SG9999015945.SGD","LU0289739699.SGD","LU1623119135.USD","LU2211815571.USD","LU2213496289.HKD","SG9999015952.SGD","IE00BN29S564.USD","LU2552382058.USD","IE0004445015.USD","LU1814569148.SGD","LU1868837300.USD","LU2087625088.SGD","LU1069344957.HKD","SG9999015986.USD","LU2023250504.SGD","LU1720051108.HKD","BK4007","LU1551013342.USD","BK4599","LU1548497426.USD","LU2602419157.SGD","LU0238689110.USD","IE0002141913.USD","IE00B1XK9C88.USD","SG9999001176.USD","LU2237443382.USD","SG9999017495.SGD","LU0787776722.HKD","LU0353189763.USD","LU0417517546.SGD","LU2108987350.USD","LU1551013425.SGD","LU0256863811.USD","BK4534","LU2456880835.USD","LU0203201768.USD","LU1093756325.SGD","LU2023251221.USD","LU0210536198.USD","LU2271345857.HKD","SG9999013999.USD","SG9999018865.SGD","LU2089984988.USD","LU1232071149.USD","LU1093756168.USD","LU0683600562.USD","LU0385154629.USD","LU2750360997.AUD","LU2471134796.USD","LU2361044949.HKD","LU0786609619.USD","LU0106261372.USD","LU1868837136.USD","LU2089283258.USD","LU0320765992.SGD","LU2237443622.USD","LU0889565916.HKD","LU0114720955.EUR","LU1983299246.USD","LU2361045086.USD","SG9999014906.USD","IE00BJJMRZ35.SGD","LU1267930730.SGD","LU2168564149.EUR","SG9999015978.USD","LU2461242641.AUD","LU0943347566.SGD","LU0203202063.USD","NVOH","LU1127390331.HKD","LU0006306889.USD","LU2896262040.SGD","LU0820561818.USD","IE00BJT1NW94.SGD","LU0079474960.USD","LU2746668461.USD","LU2746668974.SGD","IE00B4JS1V06.HKD","LU0466842654.USD","LU2471134523.USD","LU0234572021.USD","LU2357305700.SGD","LU0154236417.USD","LU1280957306.USD","SGXZ31699556.SGD","LU1712237335.SGD","LU2360106947.USD","LU0882574139.USD","LU2552382132.HKD","IE00BK4W5L77.USD","LU0061475181.USD","LU2237443978.SGD","BK4516","LU2491049909.HKD","LU1057294990.SGD","LU2237438978.USD","IE00BJJMRY28.SGD","LU0882574055.USD","LU1145028129.USD","GB00BDT5M118.USD","LU0094547139.USD","BK4532","IE00BKPKM429.USD","ELIL","LU2023250330.USD","LLY","SG9999014880.SGD","IE00BFSS7M15.SGD","LU2168564222.USD","SG9999018857.SGD","IE00B7KXQ091.USD","IE00BJLML261.HKD","ELIS","SGXZ81514606.USD","IE00BKVL7J92.USD","LU0708995401.HKD","LU2491050154.USD","IE00B775H168.HKD","LU0456855351.SGD","LU1974910355.USD","LU2462157665.USD","IE0005OL40V9.USD","LU1064131342.USD","LU2106854487.HKD","LU0158827781.USD","IE00BJJMRX11.SGD","LU0432979614.USD","LU1868836591.USD","IE00BFSS8Q28.SGD","LU2265009873.SGD","LU1366192091.USD","LU0109394709.USD","LU2756315664.SGD","LLYX","LU0320765059.SGD","LU0640476718.USD","LU1917777945.USD","LU0266013472.USD","LU0823434583.USD"],"gpt_icon":0},{"id":"2609521049","title":"諾和諾德聯合減重療法臨牀3期結果積極；輝瑞超長效GLP-1受體激動劑將啓動3期試驗…… | TIDES周報","url":"https://stock-news.laohu8.com/highlight/detail?id=2609521049","media":"药明康德","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609521049?lang=zh_tw&edition=fundamental","pubTime":"2026-02-08 07:31","pubTimestamp":1770507063,"startTime":"0","endTime":"0","summary":"CagriSema：公布3期临床试验数据诺和诺德公布全球REIMAGINE临床试验项目中REIMAGINE 2临床3期研究的主要结果。PF'3944是一款超长效、完全偏向性的GLP-1受体激动剂，是辉瑞通过近期收购Metsera所获得的管线，目前正被开发为每周单药治疗及每月治疗方案。截至第28周，PF'3944保持了与GLP-1 RA类药物一致的良好耐受性和有利的安全性特征。目前，MT1013正在中国开展针对该患者群体的3期临床研究，已入组超50%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260208073656a4896362&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260208073656a4896362&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0321505439.SGD","NVOH","LU0321505868.SGD","LU0154236417.USD","LU1066053197.SGD","BK4588","BK4144","LU0234572021.USD","BK4533","BK4534","LU1894683348.USD","PFE","SG9999013999.USD","LU1093756325.SGD","SG9999003800.SGD","LU1894683264.USD","NVO","LU1057294990.SGD","IE00BLSP4239.USD","LU0289739699.SGD","IE00BLSP4452.SGD","LU0306807586.USD","IE00BBT3K403.USD","LU1093756168.USD","LU0456855351.SGD","BK4599","LU0225284248.USD","BK4581","LU0868494617.USD","SG9999011175.SGD","SG9999001176.USD","IE00BKVL7J92.USD","IE0002270589.USD","BK4592","IE00B19Z3581.USD","BK4590","SG9999002232.USD","LU0122379950.USD","LU0225771236.USD","BK4532","SG9999001176.SGD","NVOX","BK4550","IE00BZ1G4Q59.USD","LU1066051498.USD","IE00B19Z3B42.SGD","SG9999002224.SGD","BK4568","LU0170899867.USD","LU1023059063.AUD","LU0058720904.USD","LU0306806265.USD","LU0985481810.HKD","BK4585","LU1883839398.USD","IE000M9KFDE8.USD","SGXZ57979304.SGD","BK4007"],"gpt_icon":0},{"id":"2609543571","title":"行業研究 | 2026 年 FDA 多肽新藥展望：6 款潛力產品引領行業破局","url":"https://stock-news.laohu8.com/highlight/detail?id=2609543571","media":"多肽圈","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609543571?lang=zh_tw&edition=fundamental","pubTime":"2026-02-07 09:00","pubTimestamp":1770426012,"startTime":"0","endTime":"0","summary":"过去一年里，所谓的 “Tide” 军团中仅有四款新药获得 FDA 批准，而其中的主角并非多肽，而是寡核苷酸。该药于 2025 年 9 月获得 FDA 加速批准，用于改善 Barth 综合征患者的肌力，也由此成为这一病种的首个获批治疗选择。2025 年更像是一个多肽药物的“调整期”，而非真正的高光时刻。从 FDA 已披露的新药审评进度来看，一批多肽类 NCE 以及以多肽为关键驱动的产品形态，已经接近关键节点。FDA已受理其NDA并给出2026年8月28日的PDUFA目标日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207093559a6dd821e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207093559a6dd821e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4116","IE00BZ1G4Q59.USD","LU1093756168.USD","BK4585","BK4007","BK4532","LU0154236417.USD","BK4023","BK4588","IE00BKVL7J92.USD","NVOH","LU1093756325.SGD","BK4599","NVOX","NVO"],"gpt_icon":1}],"pageSize":4,"totalPage":12,"pageCount":1,"totalSize":48,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NVOX\",params:#limit:6,delay:false,,,undefined,":[]}}